PR Newswire - Galux Unveils a Study in AI-Powered De Novo Antibo...
Pioneering AI technology successfully designs antibodies de novo for six therapeutic targets, including one without an experimentally resolved structure SEOUL, South Korea, March 17, 2025 /PRNewswir...
Read More

ภาษาไทย
English